You can buy or sell CNCE and other stocks, options, ETFs, and crypto commission-free!
Concert Pharmaceuticals, Inc. Common Stock, also called Concert Pharmaceuticals, is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Read More Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.
52 Week High
52 Week Low
Seeking AlphaMar 19
Concert Pharmaceuticals (CNCE) Investor Presentation - Slideshow
The following slide deck was published by Concert Pharmaceuticals, Inc. in conjunction with this event. 1 20 Click to enlarge Notes:...
Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. The trial is intended to inform the optimal dosing regimen for CTP-543 for future clinical trials. This open label trial follows the announcement of positive results from an interim analysis of an ongoing placebo-controlled Phase 2 trial that showed significant...
Seeking AlphaMar 1
Concert Pharmaceuticals' (CNCE) CEO Roger Tung on Q4 2018 Results - Earnings Call Transcript
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Q4 2018 Earnings Conference Call February 28, 2019 8:30 AM ET Company Participants Justine Koenigsberg – Senior Vice President, Corporate Communications and Investor Relations Roger Tung – President and Chief Executive Officer Jim Cassella – Chief Development Officer Marc Becker – Chief Financial Officer Conference Call Participants Carter Gould – UBS Alex Lim – Mizuho Adam Walsh – Stifel Operator Good morning, ladies and gentlemen, and welcome to the C...
Expected May 2, Pre-Market